Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors.
Ute M. Moll(Weatherford College), G Riou(Assistance Publique Hôpitaux de Marseille)
Cited by 433
Related Papers
Aristolochic acid and the etiology of endemic (Balkan) nephropathy
|Proceedings of the National Academy of Sciences|2007|598
Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion.
|Proceedings of the National Academy of Sciences|1992|580
p63 and p73: Roles in Development and Tumor Formation
|Molecular Cancer Research|2004|492
SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis
|Cell Death and Differentiation|2011|331
ΔNp73, A Dominant-Negative Inhibitor of Wild-type p53 and TAp73, Is Up-regulated in Human Tumors
|The Journal of Experimental Medicine|2002|317